FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137489898> ?p ?o ?g. }

• W2137489898 endingPage "1697" @default.
• W2137489898 startingPage "1687" @default.
• W2137489898 abstract "Laser treatment for diabetic retinopathy is often associated with visual field reduction and other ocular side-effects. Our aim was to assess whether long-term lipid-lowering therapy with fenofibrate could reduce the progression of retinopathy and the need for laser treatment in patients with type 2 diabetes mellitus.The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study was a multinational randomised trial of 9795 patients aged 50-75 years with type 2 diabetes mellitus. Eligible patients were randomly assigned to receive fenofibrate 200 mg/day (n=4895) or matching placebo (n=4900). At each clinic visit, information concerning laser treatment for diabetic retinopathy-a prespecified tertiary endpoint of the main study-was gathered. Adjudication by ophthalmologists masked to treatment allocation defined instances of laser treatment for macular oedema, proliferative retinopathy, or other eye conditions. In a substudy of 1012 patients, standardised retinal photography was done and photographs graded with Early Treatment Diabetic Retinopathy Study (ETDRS) criteria to determine the cumulative incidence of diabetic retinopathy and its component lesions. Analyses were by intention to treat. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN64783481.Laser treatment was needed more frequently in participants with poorer glycaemic or blood pressure control than in those with good control of these factors, and in those with a greater burden of clinical microvascular disease, but the need for such treatment was not affected by plasma lipid concentrations. The requirement for first laser treatment for all retinopathy was significantly lower in the fenofibrate group than in the placebo group (164 [3.4%] patients on fenofibrate vs 238 [4.9%] on placebo; hazard ratio [HR] 0.69, 95% CI 0.56-0.84; p=0.0002; absolute risk reduction 1.5% [0.7-2.3]). In the ophthalmology substudy, the primary endpoint of 2-step progression of retinopathy grade did not differ significantly between the two groups overall (46 [9.6%] patients on fenofibrate vs 57 [12.3%] on placebo; p=0.19) or in the subset of patients without pre-existing retinopathy (43 [11.4%] vs 43 [11.7%]; p=0.87). By contrast, in patients with pre-existing retinopathy, significantly fewer patients on fenofibrate had a 2-step progression than did those on placebo (three [3.1%] patients vs 14 [14.6%]; p=0.004). An exploratory composite endpoint of 2-step progression of retinopathy grade, macular oedema, or laser treatments was significantly lower in the fenofibrate group than in the placebo group (HR 0.66, 95% CI 0.47-0.94; p=0.022).Treatment with fenofibrate in individuals with type 2 diabetes mellitus reduces the need for laser treatment for diabetic retinopathy, although the mechanism of this effect does not seem to be related to plasma concentrations of lipids." @default.
• W2137489898 created "2016-06-24" @default.
• W2137489898 creator A5026128185 @default.
• W2137489898 creator A5028026239 @default.
• W2137489898 creator A5028039585 @default.
• W2137489898 creator A5038255184 @default.
• W2137489898 creator A5041403782 @default.
• W2137489898 creator A5041590620 @default.
• W2137489898 creator A5046649014 @default.
• W2137489898 creator A5052132754 @default.
• W2137489898 creator A5057557099 @default.
• W2137489898 creator A5073738539 @default.
• W2137489898 creator A5082061848 @default.
• W2137489898 creator A5082499488 @default.
• W2137489898 creator A5084040956 @default.
• W2137489898 creator A5084411568 @default.
• W2137489898 creator A5085146196 @default.
• W2137489898 creator A5089833703 @default.
• W2137489898 date "2007-11-01" @default.
• W2137489898 modified "2023-10-18" @default.
• W2137489898 title "Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial" @default.
• W2137489898 cites W1578810619 @default.
• W2137489898 cites W1791318806 @default.
• W2137489898 cites W1963632620 @default.
• W2137489898 cites W1977868067 @default.
• W2137489898 cites W1982191008 @default.
• W2137489898 cites W1986827231 @default.
• W2137489898 cites W1989062509 @default.
• W2137489898 cites W1992968447 @default.
• W2137489898 cites W1993742733 @default.
• W2137489898 cites W1996952739 @default.
• W2137489898 cites W2004793507 @default.
• W2137489898 cites W2008152614 @default.
• W2137489898 cites W2010019124 @default.
• W2137489898 cites W2011054533 @default.
• W2137489898 cites W2012669640 @default.
• W2137489898 cites W2016637960 @default.
• W2137489898 cites W2032687008 @default.
• W2137489898 cites W2032849378 @default.
• W2137489898 cites W2038799861 @default.
• W2137489898 cites W2039170092 @default.
• W2137489898 cites W2048284193 @default.
• W2137489898 cites W2048700739 @default.
• W2137489898 cites W2064100104 @default.
• W2137489898 cites W2064417542 @default.
• W2137489898 cites W2066896194 @default.
• W2137489898 cites W2070685907 @default.
• W2137489898 cites W2072690677 @default.
• W2137489898 cites W2077477468 @default.
• W2137489898 cites W2088714968 @default.
• W2137489898 cites W2091284231 @default.
• W2137489898 cites W2092084640 @default.
• W2137489898 cites W2099020618 @default.
• W2137489898 cites W2107436171 @default.
• W2137489898 cites W2123008267 @default.
• W2137489898 cites W2132266430 @default.
• W2137489898 cites W2140111840 @default.
• W2137489898 cites W2157677292 @default.
• W2137489898 cites W2159337738 @default.
• W2137489898 cites W2171845476 @default.
• W2137489898 cites W2198678228 @default.
• W2137489898 cites W2331000804 @default.
• W2137489898 cites W2337454357 @default.
• W2137489898 cites W2406931263 @default.
• W2137489898 cites W2591764924 @default.
• W2137489898 cites W3198570063 @default.
• W2137489898 cites W4212945288 @default.
• W2137489898 cites W4233230329 @default.
• W2137489898 cites W4234329496 @default.
• W2137489898 cites W4240531687 @default.
• W2137489898 doi "https://doi.org/10.1016/s0140-6736(07)61607-9" @default.
• W2137489898 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17988728" @default.
• W2137489898 hasPublicationYear "2007" @default.
• W2137489898 type Work @default.
• W2137489898 sameAs 2137489898 @default.
• W2137489898 citedByCount "892" @default.
• W2137489898 countsByYear W21374898982012 @default.
• W2137489898 countsByYear W21374898982013 @default.
• W2137489898 countsByYear W21374898982014 @default.
• W2137489898 countsByYear W21374898982015 @default.
• W2137489898 countsByYear W21374898982016 @default.
• W2137489898 countsByYear W21374898982017 @default.
• W2137489898 countsByYear W21374898982018 @default.
• W2137489898 countsByYear W21374898982019 @default.
• W2137489898 countsByYear W21374898982020 @default.
• W2137489898 countsByYear W21374898982021 @default.
• W2137489898 countsByYear W21374898982022 @default.
• W2137489898 countsByYear W21374898982023 @default.
• W2137489898 crossrefType "journal-article" @default.
• W2137489898 hasAuthorship W2137489898A5026128185 @default.
• W2137489898 hasAuthorship W2137489898A5028026239 @default.
• W2137489898 hasAuthorship W2137489898A5028039585 @default.
• W2137489898 hasAuthorship W2137489898A5038255184 @default.
• W2137489898 hasAuthorship W2137489898A5041403782 @default.
• W2137489898 hasAuthorship W2137489898A5041590620 @default.
• W2137489898 hasAuthorship W2137489898A5046649014 @default.
• W2137489898 hasAuthorship W2137489898A5052132754 @default.
• W2137489898 hasAuthorship W2137489898A5057557099 @default.

• next